A closer look at TICRR (C15orf42), a potential drug target and biomarker for cancer

Target Name: TICRR

NCBI ID: G90381

TICRR

A closer look at TICRR (C15orf42), a potential drug target and biomarker for cancer

Ticrr (C15orf42) is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. Its primary function is to regulate the growth and differentiation of cells, which is essential for maintaining tissue homeostasis and development. Ticrr has been identified as a potential drug target and biomarker for various diseases, including cancer. In this article, we will provide a closer look at Ticrr, its function, potential drug targets, and its potential as a biomarker for cancer.

Function and localization

Ticrr is a 21-kDa protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is primarily localized to the cytoplasm of cells and is involved in regulating the growth, differentiation, and migration of cells. Ticrr has been shown to play a role in the regulation of cell adhesion, migration, and the association with adherens junctions.

Potential drug targets

Ticrr has been identified as a potential drug target for various diseases, including cancer. One of the key reasons for its potential as a drug target is its involvement in cell signaling pathways. Ticrr has been shown to be involved in several signaling pathways that are involved in cancer development, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the Wnt signaling pathway.

In addition to its involvement in signaling pathways, Ticrr has also been shown to interact with several protein molecules that are known to be involved in cancer. For example, Ticrr has been shown to interact with the protein PDGF-BB, which is a potent oncogene that is involved in the development of various types of cancer.

Potential biomarker

Ticrr has also been identified as a potential biomarker for cancer. Its expression has been shown to be altered in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that Ticrr has been associated with poor prognosis in patients with cancer.

Methods

To study the potential drug targets of Ticrr, several approaches have been used, including gene expression analysis, protein interaction analysis, and bioinformatics analysis. Gene expression analysis was used to identify the genes that were expressed in Ticrr-expressing cells and compare them to gene expression in non-Ticrr-expressing cells. Protein interaction analysis was used to identify the protein-protein interaction interactions in Ticrr and compare them to those in non-Ticrr cells. Bioinformatics analysis was used to identify potential binding sites in Ticrr and compare them to those in non-Ticrr cells.

Conclusion

In conclusion, Ticrr is a protein that is expressed in various tissues of the body and is involved in regulating cell growth and differentiation. Its potential as a drug target and biomarker for cancer makes it an attractive target for researchers to investigate. Further studies are needed to fully understand the role of Ticrr in cancer development and to develop effective treatments.

Protein Name: TOPBP1 Interacting Checkpoint And Replication Regulator

Functions: Regulator of DNA replication and S/M and G2/M checkpoints. Regulates the triggering of DNA replication initiation via its interaction with TOPBP1 by participating in CDK2-mediated loading of CDC45L onto replication origins. Required for the transition from pre-replication complex (pre-RC) to pre-initiation complex (pre-IC). Required to prevent mitotic entry after treatment with ionizing radiation

The "TICRR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TICRR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets